Navigation Links
TAVI is safe alternative to redo cardiac surgery
Date:9/2/2013

Use of bioprosthetic heart valves has dramatically increased (from 18% in 1991 to 59% in 2003), mainly in older patients with comorbidities. This is due to the increased risk of bleeding complications associated with lifelong use of anticoagulation for mechanical prostheses.

But structural valve deterioration is one the main complications associated with bioprosthetic heart valves. In large registries including more than 300 000 patients undergoing aortic valve replacement the reoperation rate for patients receiving a bioprosthesis was 3.1% at 11-13 years of follow-up compared with 2.3% reoperation rate for recipients of an aortic mechanical prosthesis.1

Dr Katsanos said: "Reoperation for failed bioprostheses, also called redo cardiac surgery, is associated with increased rates of mortality and morbidity. Less invasive treatments have emerged such as transcatheter valve-in-valve implantation, a type of TAVI operation which is a safe therapeutic option for patients with failed bioprostheses and contraindications for surgery. But until now there has not been a direct comparison of survival between high risk patients treated with either reoperation or a TAVI operation."

The current study assessed the prognosis of patients with failed bioprosthetic aortic and mitral valves and high predicted operative risk who underwent transcatheter valve-in-valve intervention with the Edwards Sapien (23 or 26 mm) valve. They were compared with a historical cohort of patients who underwent elective redo cardiac surgery for failing mitral and aortic prostheses and failing mitral valve annuloplasty.

The TAVI group (age 802 years, 25% men) included 12 patients with failing aortic bioprostheses, 2 with failing mitral bioprostheses and 2 with failed mitral valve annuloplasty. The redo cardiac surgery group (age 701 years, 50% men) had 15 patients with failing aortic bioprostheses and 1 with failing mitral bioprostheses. The reason for valve dysfunction was stenosis in 11 patients, regurgitation in 14 patients and mixed pathology in 7 patients. Patients with endocarditis were excluded. Both groups had similar operative risk, New York Heart Association functional class, and left ventricular ejection fraction.

After a median follow up of 21 (range 7-44) months, 10 (30%) patients died. As shown in the figure, 3-year survival did not differ between patients treated with transcatheter valve-in-valve implantation and those treated with redo cardiac surgery (log-rank p=0.939).

Dr Katsanos said: "We have shown for the first time that the long term survival of high risk patients with failing bioprostheses treated with transcatheter valve-in-valve implantation is comparable to high risk patients treated with redo cardiac surgery."

He concluded: "Transcatheter valve-in-valve implantation is a minimally invasive procedure performed through transfemoral or transapical approach under fluoroscopic guidance and does not require sternotomy and cardiopulmonary bypass. Elderly patients deemed not operable and also high risk patients with failing bioprostheses may have a treatment alternative to redo cardiac surgery."


'/>"/>

Contact: Celine Colas
press@escardio.org
44-773-005-7146
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. Procedure gives patients with A-fib who cant take blood thinners alternative to reduce stroke
2. Study Supports Value of Sigmoidoscopy, an Alternative to Colonoscopy
3. Approval of Safer Alternative to Pradaxa Delayed by FDA
4. Smokers Drop Pricey Cigarettes for Cheaper Alternatives: CDC
5. Alternatives to Medicares fee-for-service payment system examined
6. NHS should replace traditional autopsies with non-invasive alternative
7. Complementary and alternative therapy improved lives of arthritis patients
8. Water Workouts a Great Alternative: Study
9. Controversial Alternative Heart Treatment Shows Hint of Benefit
10. GW researcher receives $4.1 million grant to find alternative treatment for kidney stones
11. Potential new technique for anticancer radiotherapy could provide alternative to brachytherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 23, 2017 , ... United Nations Foundation President ... the Mexico City Policy, also known as the Global Gag Rule, last enacted ... prohibits foreign non-governmental organizations from receiving any U.S. foreign assistance for family planning ...
(Date:1/24/2017)... ... 23, 2017 , ... Texas Home Health, an AccentCare, Inc. ... care service companies: Padre Home Health in Corpus Christi, Texas, and Royalty Personal ... regarded in their respective markets, these two agencies align with Texas Home Health’s ...
(Date:1/24/2017)... (PRWEB) , ... January 23, 2017 , ... ... men who support them, Dr. Carol Francis, Psychologist in the South Bay ... pay, humane respectful governing for all people and by all people shines as ...
(Date:1/24/2017)... ... , ... The National Council of Alcoholism and Drug Dependence ( NCADD ), ... communities to designate the last full week of January as National Drug and Alcohol ... Myths.” As a community, we can advocate for effective treatment, but also especially ...
(Date:1/23/2017)... ... ... PKF O’Connor Davies , LLP, the nation’s 26th largest accounting and ... will participate in the 40th Annual "Empire State Building Run Up" on Feb. 1 ... a vertical distance equal to about a fifth of a mile, to reach the ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... SAN FRANCISCO , January 23, 2017 The global  ... USD 18.3 billion by 2025. The rising incidence of depression worldwide is anticipated ... and psychotherapies has resulted in the declining demand for antidepressants in the recent ... ... Grand View Research Logo ...
(Date:1/23/2017)... Januar 2017  ResMed (NYSE: RMD ), ... Medical ( Winter Haven, Florida ) gaben ... die Beilegung aller globalen Rechtsstreitigkeiten zwischen den Parteien geeinigt ... ihrer bestehenden Produkte im Tausch gegen Lizenzgebühren an ResMed ... leisten, um das in Florida ...
(Date:1/23/2017)... , Jan 23, 2017 NeuroVive Pharmaceutical ... has signed a preclinical collaboration agreement with the Children,s Hospital ... J. Falk , M.D., a US key opinion leader in ... ... will evaluate compounds from NeuroVive,s research program, NVP015, in certain ...
Breaking Medicine Technology: